Southlake, TX — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW), a medical technology company focused on saving lives by making an ECG a far more valuable screening tool through the use of artificial intelligence, today announced it has been granted a patent in Israel (Patent No. 10-2490960) from the Israel Patent Office.
"Artificial intelligence is transforming what's possible, and at HeartSciences we are at the leading edge of changing what's possible with an ECG by applying AI to make it a far more valuable screening tool for heart disease detection to save lives. Israel is a hotbed for medical device innovation, with more patents granted per capita than anywhere else worldwide. This patent award further protects our IP and further validates our position as a technology innovator," said Andrew Simpson, CEO of HeartSciences.
To date, HeartSciences has been granted nine US patents and 31 international patents for a total of 40 granted patents, with 8 additional patents pending across the US and international markets.
Investor contact
Mark Komonoski, Integrous Communications · 877-255-8483 · [email protected]